Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccine
The European Commission accepted binding commitments after investigating Sanofi’s communications about a rival influenza vaccine.
TL;DR
- The Commission accepted Sanofi commitments to resolve an antitrust investigation into communications about CSL Seqirus’s Fluad vaccine.
- It had raised concerns that messages in Germany and France portrayed Fluad as inferior to Sanofi’s Efluelda.
- Sanofi agreed to corrective communications and to refrain from similar conduct; it avoided a fine.
STAT and El País reported October 14 that the Commission accepted Sanofi’s commitments and closed its investigation without a fine. The case concerned communications about rival influenza vaccines. [1] [2]
The Commission’s concerns focused on whether promotional messages could mislead health professionals about Fluad, marketed by CSL Seqirus, compared with Sanofi’s Efluelda in Germany and France. This was a regulatory concern, not a court finding. [1] [2]
Sanofi committed to a corrective campaign and to refrain from the conduct. STAT reported that the agreement is legally binding; the outcome was accepted commitments rather than a monetary penalty. [1] [2]
The case concerns competition and promotion in the influenza-vaccine market. The resolution does not compare clinical performance or change indications; no patient-outcome conclusion follows. [1] [2]
Why it matters
The resolution shows how competition oversight can constrain vaccine promotion in a market where the Commission said one supplier held a dominant position in two national markets.
Editor's note
The reports do not establish a clinical comparison between vaccines.